Literature DB >> 20973920

Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Michael G Risbano1, Christina A Meadows, Christopher D Coldren, Tiffany J Jenkins, Michael G Edwards, David Collier, Wendy Huber, Douglas G Mack, Andrew P Fontenot, Mark W Geraci, Todd M Bull.   

Abstract

Pulmonary arterial hypertension is a common and fatal complication of scleroderma that may involve inflammatory and autoimmune mechanisms. Alterations in the gene expression of peripheral blood mononuclear cells have been previously described in patients with pulmonary arterial hypertension. Our goal is to identify differentially expressed genes in peripheral blood mononuclear cells in scleroderma patients with and without pulmonary hypertension as biomarkers of disease. Gene expression analysis was performed on a Microarray Cohort of scleroderma patients with (n = 10) and without (n = 10) pulmonary hypertension. Differentially expressed genes were confirmed in the Microarray Cohort and validated in a Validation Cohort of scleroderma patients with (n = 15) and without (n = 19) pulmonary hypertension by RT-qPCR. We identified inflammatory and immune-related genes including interleukin-7 receptor (IL-7R) and chemokine receptor 7 as differentially expressed in patients with scleroderma-associated pulmonary hypertension. Flow cytometry confirmed decreased expression of IL-7R on circulating CD4+ T-cells from scleroderma patients with pulmonary hypertension. Differences exist in the expression of inflammatory and immune-related genes in peripheral blood cells from patients with scleroderma-related pulmonary hypertension compared to those with normal pulmonary artery pressures. These findings may have implications as biomarkers to screen at-risk populations for early diagnosis and provide insight into mechanisms of scleroderma-related pulmonary hypertension.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20973920      PMCID: PMC2966033          DOI: 10.1111/j.1752-8062.2010.00218.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN: 1752-8054            Impact factor:   4.689


  45 in total

1.  Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension.

Authors:  Amy Richter; Michael E Yeager; Ari Zaiman; Carlyne D Cool; Norbert F Voelkel; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2004-09-10       Impact factor: 21.405

2.  Autoantibodies in patients with primary pulmonary hypertension: association with anti-Ku.

Authors:  R A Isern; M Yaneva; E Weiner; A Parke; N Rothfield; D Dantzker; S Rich; F C Arnett
Journal:  Am J Med       Date:  1992-09       Impact factor: 4.965

3.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

4.  Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension.

Authors:  M Fartoukh; D Emilie; C Le Gall; G Monti; G Simonneau; M Humbert
Journal:  Chest       Date:  1998-07       Impact factor: 9.410

5.  Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.

Authors:  C D Cool; D Kennedy; N F Voelkel; R M Tuder
Journal:  Hum Pathol       Date:  1997-04       Impact factor: 3.466

6.  The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4.

Authors:  L B Zimmerman; J M De Jesús-Escobar; R M Harland
Journal:  Cell       Date:  1996-08-23       Impact factor: 41.582

7.  Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.

Authors:  J H Morse; R J Barst; M Fotino; Y Zhang; E Flaster; A E Gharavi; M J Fritzler; M Dominguez; E Angles-Cano
Journal:  Am J Respir Crit Care Med       Date:  1997-01       Impact factor: 21.405

8.  Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency.

Authors:  A Puel; S F Ziegler; R H Buckley; W J Leonard
Journal:  Nat Genet       Date:  1998-12       Impact factor: 38.330

9.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.

Authors:  M Humbert; G Monti; F Brenot; O Sitbon; A Portier; L Grangeot-Keros; P Duroux; P Galanaud; G Simonneau; D Emilie
Journal:  Am J Respir Crit Care Med       Date:  1995-05       Impact factor: 21.405

10.  The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis.

Authors:  A E Corcoran; F M Smart; R J Cowling; T Crompton; M J Owen; A R Venkitaraman
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

View more
  28 in total

1.  Meta-analysis of blood genome-wide expression profiling studies in pulmonary arterial hypertension.

Authors:  Jason M Elinoff; Adrien J Mazer; Rongman Cai; Mengyun Lu; Grace Graninger; Bonnie Harper; Gabriela A Ferreyra; Junfeng Sun; Michael A Solomon; Robert L Danner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

2.  Regulatory T-cell detection by flow cytometry and systemic sclerosis.

Authors:  Sujoy Khan
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

3.  Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls
Journal:  Circulation       Date:  2019-08-29       Impact factor: 29.690

Review 4.  Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.

Authors:  Jessica B Badlam; Todd M Bull
Journal:  Ther Adv Chronic Dis       Date:  2017-03-01       Impact factor: 5.091

5.  Expression profiling elucidates a molecular gene signature for pulmonary hypertension in sarcoidosis.

Authors:  Sunit Singla; Tong Zhou; Kamran Javaid; Taimur Abbasi; Nancy Casanova; Wei Zhang; Shwu-Fan Ma; Michael S Wade; Imre Noth; Nadera J Sweiss; Joe G N Garcia; Roberto F Machado
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

6.  The mechanistic implications of gene expression studies in SSc: Insights from Systems Biology.

Authors:  Jaclyn N Taroni; J Matthew Mahoney; Michael L Whitfield
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-07-29

7.  Association of circulating transcriptomic profiles with mortality in sickle cell disease.

Authors:  Ankit A Desai; Zhengdeng Lei; Neil Bahroos; Mark Maienschein-Cline; Santosh L Saraf; Xu Zhang; Binal N Shah; Seyed M Nouraie; Taimur Abbasi; Amit R Patel; Roberto M Lang; Yves Lussier; Joe G N Garcia; Victor R Gordeuk; Roberto F Machado
Journal:  Blood       Date:  2017-04-03       Impact factor: 22.113

Review 8.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

9.  A Review of Transcriptome Analysis in Pulmonary Vascular Diseases.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Methods Mol Biol       Date:  2018

10.  Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis.

Authors:  Jose D Herazo-Maya; Imre Noth; Steven R Duncan; Sunghwan Kim; Shwu-Fan Ma; George C Tseng; Eleanor Feingold; Brenda M Juan-Guardela; Thomas J Richards; Yves Lussier; Yong Huang; Rekha Vij; Kathleen O Lindell; Jianmin Xue; Kevin F Gibson; Steven D Shapiro; Joe G N Garcia; Naftali Kaminski
Journal:  Sci Transl Med       Date:  2013-10-02       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.